Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07655362Phase 3Not Yet Recruiting

Baxdrostat and Ventricular Remodeling

Role: lead

NCT07270367Phase 3Not Yet Recruiting

Finerenone and Cardiac Remodeling

Role: lead

NCT06955260Phase 3Not Yet Recruiting

SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

Role: lead

All 3 trials loaded